United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 59.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,802 shares of the biotechnology company’s stock after selling 32,297 shares during the period. United Therapeutics makes up 1.9% of Eagle Health Investments LP’s portfolio, making the stock its 14th biggest position. Eagle Health Investments LP’s holdings in United Therapeutics were worth $7,693,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of United Therapeutics by 11.4% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 32,246 shares of the biotechnology company’s stock worth $11,490,000 after acquiring an additional 3,312 shares during the last quarter. Korea Investment CORP raised its position in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock valued at $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Florida Financial Advisors LLC boosted its stake in shares of United Therapeutics by 6.2% during the 4th quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 48 shares during the last quarter. Prudential Financial Inc. grew its position in shares of United Therapeutics by 22.2% during the fourth quarter. Prudential Financial Inc. now owns 66,541 shares of the biotechnology company’s stock worth $23,478,000 after buying an additional 12,104 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock worth $1,567,253,000 after buying an additional 32,213 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $919,164.36. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company’s stock, valued at $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,755 shares of company stock valued at $29,792,021 in the last quarter. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $310.82 on Thursday. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The company has a 50-day simple moving average of $342.26 and a 200-day simple moving average of $356.31. The firm has a market capitalization of $13.96 billion, a P/E ratio of 13.65, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.